ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of “Buy” from Analysts

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been given a consensus rating of “Buy” by the eight brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $77.71.

ANIP has been the topic of a number of research reports. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Piper Sandler assumed coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price objective for the company. Leerink Partners started coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price on the stock. Truist Financial lifted their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, November 11th.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $58.46 on Tuesday. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The business has a fifty day moving average of $56.30 and a 200 day moving average of $58.78. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -106.29 and a beta of 0.73. ANI Pharmaceuticals has a 1 year low of $52.50 and a 1 year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. During the same quarter in the previous year, the company posted $1.05 earnings per share. The company’s revenue was up 12.5% compared to the same quarter last year. As a group, research analysts expect that ANI Pharmaceuticals will post 3.87 earnings per share for the current year.

Insider Activity

In related news, CEO Nikhil Lalwani sold 33,481 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the transaction, the chief executive officer now directly owns 370,378 shares of the company’s stock, valued at approximately $21,478,220.22. This represents a 8.29 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen P. Carey sold 7,500 shares of the firm’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the transaction, the chief financial officer now owns 154,468 shares in the company, valued at $8,617,769.72. The trade was a 4.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,381 shares of company stock worth $2,441,556 in the last quarter. Corporate insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of ANI Pharmaceuticals by 24.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after acquiring an additional 579 shares during the period. XTX Topco Ltd purchased a new position in ANI Pharmaceuticals during the second quarter worth about $207,000. HighTower Advisors LLC acquired a new position in ANI Pharmaceuticals in the 3rd quarter valued at about $222,000. Profund Advisors LLC purchased a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at approximately $225,000. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $228,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.